Institutional
Vestal Point Capital, LP
CIK 0001974915
$3.58B
Reported AUM
90
Positions
Q1 2026
Period
2026-05-15
Filed
The Brief · Vestal Point Capital, LP · Q1 2026
AI · grounded in 13F
Vestal Point Capital, LP exited its position in Invesco QQQ Trust Series 1 QQQ, reducing exposure by $215M. The fund also closed positions in Arcellx Inc ACLXGBX for $190.7M and Dexcom Inc DXCM for $84.6M. On the buy side, the fund established a new position in Neurocrine Biosciences Inc NBIX worth $164.7M and increased its holdings in Repligen Corp RGEN by 1,014.46%.
Portfolio · Q1 2026
Top holdings
QoQ vs Q4 2025
| # | Ticker | Issuer | Value | % of book | Δ shares (QoQ) | Status |
|---|---|---|---|---|---|---|
| 1 | RVMD | Revolution Medicines Inc | $231.0M | 6.46% | +2,080,000 | +705.1% |
| 2 | BMRN | BioMarin Pharmaceutical Inc | $202.0M | 5.65% | +575,000 | +19.2% |
| 3 | ABVX | Abivax SA | $167.0M | 4.67% | -400,000 | -21.1% |
| 4 | NBIX | Neurocrine Biosciences Inc | $164.7M | 4.60% | +1,250,000 | NEW |
| 5 | ARWR | Arrowhead Pharmaceuticals Inc | $142.6M | 3.99% | +1,375,000 | +152.8% |
| 6 | ELVN | Enliven Therapeutics Inc | $127.4M | 3.56% | -580,000 | -15.1% |
| 7 | RGEN | Repligen Corp | $109.0M | 3.05% | +842,000 | +1014.5% |
| 8 | BCAX | Bicara Therapeutics Inc | $107.9M | 3.02% | +1,850,000 | +51.7% |
| 9 | NRIX | Nurix Therapeutics Inc | $100.8M | 2.82% | +1,810,000 | +38.6% |
| 10 | APGE | Apogee Therapeutics Inc | $92.6M | 2.59% | +550,000 | +100.0% |
| 11 | ASNDUSD | Ascendis Pharma A/S | $85.8M | 2.40% | +200,000 | +114.3% |
| 12 | IMCR | Immunocore Holdings PLC | $83.4M | 2.33% | +2,181,868 | +373.0% |
| 13 | TSHA | Taysha Gene Therapies Inc | $80.5M | 2.25% | +4,250,000 | +30.9% |
| 14 | DYN | Dyne Therapeutics Inc | $72.5M | 2.03% | +3,880,000 | +3233.3% |
| 15 | SNY | Sanofi SA | $67.5M | 1.89% | +1,400,000 | NEW |
| 16 | BCRX | BioCryst Pharmaceuticals Inc | $66.9M | 1.87% | +4,775,000 | +212.2% |
| 17 | SRRK | Scholar Rock Holding Corp | $65.1M | 1.82% | +624,422 | +89.2% |
| 18 | IMTX | Immatics NV | $60.8M | 1.70% | +50,000 | +0.8% |
| 19 | BMY | Bristol-Myers Squibb Co | $60.6M | 1.70% | +750,000 | +300.0% |
| 20 | ALC | Alcon AG | $60.3M | 1.69% | -305,000 | -27.6% |
| 21 | GLUE | Monte Rosa Therapeutics Inc | $59.3M | 1.66% | +2,828,465 | +365.0% |
| 22 | VERA | Vera Therapeutics Inc | $55.0M | 1.54% | +818,159 | +148.8% |
| 23 | 430 | Terns Pharmaceuticals Inc | $52.7M | 1.47% | -3,500,000 | -77.8% |
| 24 | GMED | Globus Medical Inc | $52.6M | 1.47% | -664,480 | -52.1% |
| 25 | BSX | Boston Scientific Corp | $50.2M | 1.40% | +800,000 | NEW |
| 26 | NUVL | Nuvalent Inc | $49.4M | 1.38% | +435,715 | +947.2% |
| 27 | COGT | Cogent Biosciences Inc | $47.4M | 1.32% | +1,230,888 | NEW |
| 28 | ANRO | Alto Neuroscience Inc | $46.4M | 1.30% | -420,925 | -16.9% |
| 29 | RAPP | Rapport Therapeutics Inc | $44.9M | 1.26% | +326,229 | +29.4% |
| 30 | IRON | Disc Medicine Inc | $44.8M | 1.25% | -35,000 | -4.8% |
| 31 | UTHR | United Therapeutics Corp | $44.5M | 1.24% | +75,000 | NEW |
| 32 | CLDX | Celldex Therapeutics Inc | $38.8M | 1.09% | +59,165 | +5.1% |
| 33 | KALV | KalVista Pharmaceuticals Inc | $37.2M | 1.04% | -40,000 | -2.1% |
| 34 | XENE | Xenon Pharmaceuticals Inc | $37.2M | 1.04% | +39,900 | +6.7% |
| 35 | SLDB | Solid Biosciences Inc | $36.0M | 1.01% | -815,000 | -14.0% |
| 36 | DRUG | Bright Minds Biosciences Inc | $35.9M | 1.00% | +492,319 | NEW |
| 37 | PTGX | Protagonist Therapeutics Inc | $34.4M | 0.96% | +326,159 | NEW |
| 38 | DNLI | Denali Therapeutics Inc | $34.0M | 0.95% | +1,308,326 | +281.4% |
| 39 | REGN | Regeneron Pharmaceuticals Inc | $30.9M | 0.86% | +40,000 | NEW |
| 40 | WAT | Waters Corp | $29.8M | 0.83% | +100,000 | NEW |
| 41 | VKTX | Viking Therapeutics Inc | $29.7M | 0.83% | +914,147 | NEW |
| 42 | INSP | Inspire Medical Systems Inc | $27.8M | 0.78% | +539,269 | NEW |
| 43 | CBIO | Crescent Biopharma Inc | $27.6M | 0.77% | — | HELD |
| 44 | TRVI | Trevi Therapeutics Inc | $25.8M | 0.72% | +2,166,504 | NEW |
| 45 | LXEO | Lexeo Therapeutics Inc | $25.7M | 0.72% | — | HELD |
| 46 | SLNO | Soleno Therapeutics Inc | $24.4M | 0.68% | +730,000 | NEW |
| 47 | BBNX | Beta Bionics Inc | $22.2M | 0.62% | +1,611,518 | +268.6% |
| 48 | NKTR | Nektar Therapeutics | $20.5M | 0.57% | +285,000 | NEW |
| 49 | CYTK | Cytokinetics Inc | $19.8M | 0.55% | +300,000 | NEW |
| 50 | AZN | AstraZeneca PLC | $19.7M | 0.55% | +100,000 | NEW |
| 51 | WST | West Pharmaceutical Services I | $18.8M | 0.53% | +75,000 | NEW |
| 52 | GEHC | GE HealthCare Technologies Inc | $17.8M | 0.50% | +250,000 | NEW |
| 53 | SGP | SpyGlass Pharma Inc | $17.3M | 0.48% | +666,760 | NEW |
| 54 | ZBH | Zimmer Biomet Holdings Inc | $17.2M | 0.48% | +40,000 | +26.7% |
| 55 | MDGL | Madrigal Pharmaceuticals Inc | $16.5M | 0.46% | +31,468 | NEW |
| 56 | WGS | GeneDx Holdings Corp | $16.1M | 0.45% | +250,000 | NEW |
| 57 | DMRA | Damora Therapeutics Inc | $15.5M | 0.43% | +600,000 | NEW |
| 58 | AGIO | Agios Pharmaceuticals Inc | $15.2M | 0.43% | +125,000 | +38.5% |
| 59 | — | enGene Therapeutics Inc | $14.7M | 0.41% | +1,110,000 | +105.2% |
| 60 | SVRA | Savara Inc | $14.2M | 0.40% | +994,052 | +61.9% |
| 61 | TARS | Tarsus Pharmaceuticals Inc | $14.0M | 0.39% | +200,000 | NEW |
| 62 | VYGR | Voyager Therapeutics Inc | $11.6M | 0.32% | +1,527,936 | +103.6% |
| 63 | PODD | Insulet Corp | $10.6M | 0.30% | +50,601 | NEW |
| 64 | TECX | Tectonic Therapeutic Inc | $10.1M | 0.28% | — | HELD |
| 65 | SRZN | Surrozen Inc | $9.9M | 0.28% | +338,611 | NEW |
| 66 | ARVN | Arvinas Inc | $9.6M | 0.27% | +905,465 | NEW |
| 67 | MPLT | MapLight Therapeutics Inc | $8.5M | 0.24% | +35,000 | +9.1% |
| 68 | FULC | Fulcrum Therapeutics Inc | $8.4M | 0.24% | +150,000 | +15.8% |
| 69 | OKUR | OnKure Therapeutics Inc | $7.6M | 0.21% | +1,204,819 | +189.7% |
| 70 | MYGN | Myriad Genetics Inc | $7.4M | 0.21% | +425,000 | +34.8% |
| 71 | OLMA | Olema Pharmaceuticals Inc | $6.4M | 0.18% | -1,221,449 | -74.0% |
| 72 | AVR | Anteris Technologies Global Co | $6.4M | 0.18% | +1,144,780 | NEW |
| 73 | QURE | uniQure NV | $5.9M | 0.16% | +358,996 | NEW |
| 74 | CADL | Candel Therapeutics Inc | $5.5M | 0.15% | +1,125,000 | NEW |
| 75 | PALI | Palisade Bio Inc | $4.4M | 0.12% | +2,500,000 | NEW |
| 76 | VCYT | Veracyte Inc | $4.2M | 0.12% | +130,687 | NEW |
| 77 | ZBIO | Zenas Biopharma Inc | $3.9M | 0.11% | +200,000 | NEW |
| 78 | GERN | Geron Corp | $3.8M | 0.11% | -8,780,000 | -77.6% |
| 79 | MNPR | Monopar Therapeutics Inc | $3.6M | 0.10% | +65,418 | NEW |
| 80 | ZURA | Zura Bio Ltd | $3.0M | 0.09% | +511,000 | NEW |
| 81 | NVCR | Novocure Ltd | $2.7M | 0.08% | -275,000 | -52.4% |
| 82 | NYXH | Nyxoah SA | $2.5M | 0.07% | -238,339 | -21.5% |
| 83 | URGN | UroGen Pharma Ltd | $2.5M | 0.07% | +139,079 | NEW |
| 84 | PASG | Passage Bio Inc | $2.4M | 0.07% | — | HELD |
| 85 | TYRA | Tyra Biosciences Inc | $2.1M | 0.06% | -2,371,000 | -97.8% |
| 86 | RGNX | REGENXBIO Inc | $909K | 0.03% | +74,525 | +219.2% |
| 87 | TENX | Tenax Therapeutics Inc | $854K | 0.02% | — | HELD |
| 88 | MGNX | MacroGenics Inc | $809K | 0.02% | — | HELD |
| 89 | ABSI | Absci Corp | $697K | 0.02% | +232,219 | NEW |
| 90 | APRE | Aprea Therapeutics Inc | $267K | 0.01% | +350,000 | NEW |
| 91 | QQQ | Invesco QQQ Trust Series 1 | — | — | -350,000 | EXITED |
| 92 | ACLXGBX | Arcellx Inc | — | — | -2,925,000 | EXITED |
| 93 | DXCM | Dexcom Inc | — | — | -1,275,000 | EXITED |
| 94 | MRK | Merck & Co Inc | — | — | -775,000 | EXITED |
| 95 | ABT | Abbott Laboratories | — | — | -600,000 | EXITED |
| 96 | JAZZ | Jazz Pharmaceuticals PLC | — | — | -290,000 | EXITED |
| 97 | DAWNGBX | Day One Biopharmaceuticals Inc | — | — | -5,200,000 | EXITED |
| 98 | AXSM | Axsome Therapeutics Inc | — | — | -210,000 | EXITED |
| 99 | LNTH | Lantheus Holdings Inc | — | — | -360,000 | EXITED |
| 100 | ZYME | Zymeworks Inc | — | — | -865,000 | EXITED |
| 101 | UPB | Upstream Bio Inc | — | — | -720,000 | EXITED |
| 102 | PEN | Penumbra Inc | — | — | -50,000 | EXITED |
| 103 | BRD1EUR | Definium Therapeutics Inc | — | — | -637,000 | EXITED |
| 104 | GILD | Gilead Sciences Inc | — | — | -50,000 | EXITED |
| 105 | DBVT | DBV Technologies SA | — | — | -300,000 | EXITED |
| 106 | MIRM | Mirum Pharmaceuticals Inc | — | — | -66,000 | EXITED |
| 107 | LENZ | LENZ Therapeutics Inc | — | — | -275,000 | EXITED |
| 108 | RZLT | Rezolute Inc | — | — | -1,686,000 | EXITED |
| 109 | STRO | Sutro Biopharma Inc | — | — | -243,000 | EXITED |
| 110 | GPCR | Structure Therapeutics Inc | — | — | -35,000 | EXITED |
| 111 | BDTX | Black Diamond Therapeutics Inc | — | — | -870,000 | EXITED |
| 112 | FATE | Fate Therapeutics Inc | — | — | -1,725,000 | EXITED |
| 113 | ALEC | Alector Inc | — | — | -755,000 | EXITED |
Source: SEC EDGAR · accession 0001974915-26-000004. 13F discloses long positions only — shorts, foreign equities, and options are excluded.